By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


CASI Pharmaceuticals (Formerly Known As EntreMed, Inc.) 

9620 Medical Center Drive

Rockville  Maryland  20850  U.S.A.
Phone: 240-864-2600 Fax: 301-315-2437


Company News
CASI Pharmaceuticals  (CASI) Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3/30/2015 6:01:52 AM
CASI Pharmaceuticals  (CASI) Reports 2014 Fourth Quarter And Full Year Financial Results 3/27/2015 7:31:17 AM
CASI Pharmaceuticals  (CASI) Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 3/25/2015 6:19:46 AM
CASI Pharmaceuticals  (CASI) Appoints Rong Chen, MD, Ph.D. As Chief Medical Officer 3/4/2015 6:53:04 AM
CASI Pharmaceuticals  (CASI) To Present At The 27th Annual ROTH Conference 3/3/2015 10:28:11 AM
CASI Pharmaceuticals  (CASI) Announces Receipt Of Final Minutes From FDA Meeting Regarding Clinical And Regulatory Path Of ENMD-2076 For The Treatment Of Patients With Fibrolamellar Carcinoma (FLC) 2/9/2015 11:48:22 AM
CASI Pharmaceuticals  (CASI) To Present At The 17th Annual BIO CEO & Investor Conference 2/2/2015 11:41:22 AM
CASI Pharmaceuticals  (CASI) Highlights 2014 Accomplishments And 2015 Milestones 1/16/2015 9:48:47 AM
CASI Pharmaceuticals  (CASI) To Hold Business Update Conference Call And Webcast On January 6th 12/23/2014 8:19:29 AM
CASI Pharmaceuticals  (CASI) Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 12/17/2014 9:53:11 AM